Metabolic abnormalities in pituitary adenoma patients: a novel therapeutic target and prognostic factor.
Metabolic abnormalities are common in cancers, and targeting metabolism is emerging as a novel therapeutic approach to cancer management. Pituitary adenoma (PA) is a type of benign tumor. Impairment of tumor cells' metabolism in PA seems not to be as apparent as that of other malignant tumor cells; however, aberrant hormone secretion is conspicuous in most PAs. Hormones have direct impacts on systemic metabolism, which in turn, may affect the progression of PA. Nowadays, conventional therapeutic strategies for PA do not include modalities of adjusting whole-body metabolism, which is most likely due to the current consideration of the aberrant whole-body metabolism of PA patients as a passive associated symptom and not involved in PA progression. Because systemic metabolic abnormalities are presented by 22.3%-52.5% PA patients and are closely correlated with disease progression and prognosis, we propose that assessment of metabolic status should be emphasized during the treatment of PA and that control of metabolic abnormalities should be added into the current therapies for PA.
Department of Neurosurgery, Xinqiao Hospital, Third Military Medical University, Shapingba District, Chongqing, People's Republic of China.
Xin
X
Zheng
Department of Neurosurgery, Xinqiao Hospital, Third Military Medical University, Shapingba District, Chongqing, People's Republic of China.
Song
S
Li
Department of Biology and Biochemistry, University of Houston, Houston, TX, USA.
Wei-Hua
WH
Zhang
Department of Neurosurgery, Xinqiao Hospital, Third Military Medical University, Shapingba District, Chongqing, People's Republic of China.
Hui
H
Yang
metabolic abnormalities; pituitary adenoma; prognostic factor; therapeutic target